GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Proteostasis Therapeutics Inc (NAS:PTI) » Definitions » Quick Ratio

Proteostasis Therapeutics (Proteostasis Therapeutics) Quick Ratio : 6.76 (As of Sep. 2020)


View and export this data going back to 2016. Start your Free Trial

What is Proteostasis Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Proteostasis Therapeutics's quick ratio for the quarter that ended in Sep. 2020 was 6.76.

Proteostasis Therapeutics has a quick ratio of 6.76. It generally indicates good short-term financial strength.

The historical rank and industry rank for Proteostasis Therapeutics's Quick Ratio or its related term are showing as below:

PTI's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.53
* Ranked among companies with meaningful Quick Ratio only.

Proteostasis Therapeutics Quick Ratio Historical Data

The historical data trend for Proteostasis Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proteostasis Therapeutics Quick Ratio Chart

Proteostasis Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Quick Ratio
Get a 7-Day Free Trial 1.52 10.31 7.70 14.05 6.88

Proteostasis Therapeutics Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.89 6.88 7.26 6.69 6.76

Competitive Comparison of Proteostasis Therapeutics's Quick Ratio

For the Biotechnology subindustry, Proteostasis Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proteostasis Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Proteostasis Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Proteostasis Therapeutics's Quick Ratio falls into.



Proteostasis Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Proteostasis Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Quick Ratio (A: Dec. 2019 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(70.871-0)/10.3
=6.88

Proteostasis Therapeutics's Quick Ratio for the quarter that ended in Sep. 2020 is calculated as

Quick Ratio (Q: Sep. 2020 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(41.573-0)/6.152
=6.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proteostasis Therapeutics  (NAS:PTI) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Proteostasis Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Proteostasis Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Proteostasis Therapeutics (Proteostasis Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
80 Guest Street, Suite 500, 5th Floor, Boston, MA, USA, 02135
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.
Executives
Franklin M Berger director 1000 MARINA BLVD, STE 200, BRISBANE CA 94005
Badrul A. Chowdhury director PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jeffrey W. Kelly director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Emmanuel Dulac director PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
David Arkowitz director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Michael Alfieri officer: Interim Head of Finance C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Greffrey S. Gilmartin officer: Chief Medical Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Meenu Chhabra director, officer: President and CEO C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
Sheila Wilson officer: Chief Operating Officer C/O PROTEOSTASIS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 500, BOSTON MA 02135
Benito Munoz officer: Chief Scientific Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Eric D Larson officer: See Remarks C/O NORTHERN POWER SYSTEMS CORP., 29 PITMAN ROAD, BARRE VT 05641
Marija Zecevic officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 12, Limited Partnership 10 percent owner 1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

Proteostasis Therapeutics (Proteostasis Therapeutics) Headlines

From GuruFocus